Ramaswamy: "Our goal is to continue to build the pipeline to fight all aspects of disease for all forms of dementia."

Ramaswamy: "The problem we are trying to solve is that of drugs that would have never seen the light of day for reasons that have nothing to do with the inherent properties of drug candidates themselves and more to do with bureaucratic institutions within which they often sit."

Ramaswamy: "The most important ingredient for the success of any company is the quality of its people, starting with its leadership team."

Ramaswamy: "I've said all along that we're building Axovant as a lasting company for the long run, not to hand over that upside to a pharma company in the future."

Ramaswamy: "I believe the pharma company of the future isn't going to be old-school."

Ramaswamy: "I think dementia is the major healthcare threat to our economy and our security. It's a ticking time bomb - we have a whole generation of baby boomers that are going to age, many progressing to get Alzheimer's - which disproportionately affects women and minorities."

Ramaswamy: "I really was inspired by the possibility of more directly being involved in the development of drugs myself."

Ramaswamy: "I would think the correlation between an era of increased globalization and an increased desire to participate in an entrepreneurial endeavor is not a coincidence. When interconnectedness is at a peak due to technological advances, the ability to spawn something new is slightly easier."

Ramaswamy: "For some companies, going public makes the most sense. For others, remaining private is preferable."

Ramaswamy: "There is probably a promising drug candidate that has already been discovered for the treatment of Down syndrome that is sitting on the shelf of some drug company."

Ramaswamy: "There is no doubt that the Mindset failure is a major setback for Axovant, but it is not the end of the road."